Last quarter (Q4 2022), Zelira Therapeutics's total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, Zelira Therapeutics's net income was AU$―. See Zelira Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19	Jun 18
Total Revenue	-	AU$ 1.54M	AU$ 432.57K	-	-	-
Cost of Revenue	-	AU$ 939.05K	AU$ 228.22K	-	-	-
Gross Profit	-	AU$ 601.57K	AU$ 204.35K	-	-	-
Operating Expense	-	AU$ 14.25M	AU$ 10.20M	AU$ 7.94M	AU$ 4.24M	AU$ 2.83M
Operating Income	-	AU$ -13.65M	AU$ -9.99M	AU$ -7.94M	AU$ -4.24M	AU$ -2.83M
Net Non Operating Interest Income Expense	-	AU$ -43.25K	AU$ -41.90K	AU$ -3.74K	AU$ 90.14K	AU$ 138.57K
Other Income Expense	-	AU$ 1.28M	AU$ 1.48M	AU$ 925.49K	AU$ 580.44K	AU$ 959.82K
Pretax Income	-	AU$ -12.41M	AU$ -8.55M	AU$ -7.02M	AU$ -3.57M	AU$ -1.73M
Tax Provision	-	AU$ 0.00	AU$ 0.00	AU$ 0.00	AU$ 0.00	AU$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	AU$ -11.95M	AU$ -8.55M	AU$ -7.02M	AU$ -3.57M	AU$ -1.73M
Basic EPS	-	AU$ -1.54	AU$ -1.28	AU$ -1.45	AU$ >-0.01	-
Diluted EPS	-	AU$ -1.54	AU$ -1.28	AU$ -1.45	AU$ >-0.01	-
Basic Average Shares	-	AU$ 8.04M	AU$ 6.63M	AU$ 4.85M	AU$ 755.07M	-
Diluted Average Shares	-	AU$ 8.04M	AU$ 6.63M	AU$ 4.85M	AU$ 755.07M	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	-	-	-	-	-
Net Income From Continuing And Discontinued Operation	-	AU$ -11.95M	AU$ -8.55M	AU$ -7.02M	AU$ -3.57M	AU$ -1.73M
Normalized Income	-	AU$ -11.95M	AU$ -8.55M	AU$ -7.02M	AU$ -3.57M	AU$ -1.73M
Interest Expense	-	AU$ 53.85K	AU$ 42.63K	AU$ 12.34K	-	-
EBIT	-	AU$ -12.36M	AU$ -8.51M	AU$ -7.00M	AU$ -4.24M	AU$ -2.83M
EBITDA	-	AU$ -11.77M	AU$ -8.03M	AU$ -6.73M	AU$ -4.24M	AU$ -2.83M

Currency in AUD

Zelira Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing